1. ALBATROSS
Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then oral spironolactone 25 mg daily for 6 months (n = 802) vs. control (n = 801).
Results
(p = 0.97)
Death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for implantable defibrillator, or new/worsening heart failure at 6 months: 11.8% of the spironolactone group vs. 12.2% of the control group (p = 0.97)
12.2
11.8 %
Conclusions
Among patients with MI without heart failure, an early aldosterone antagonist (IV potassium canrenoate/oral spironolactone) was not beneficial at reducing adverse cardiac events compared with control
Spironolactone
Control
Presented by Dr. Gilles Montalescot at ESC 2015